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treat PTCL-not otherwise specified, angioimmunoblastic T-cell lymphoma, adult 
T-cell leukemia/lymphoma, and anaplastic large cell lymphoma patients. There 
was absence of consensus regarding standard therapeutic measures. Randomized 
controlled trials comparing different treatment approaches for PTCL are very lim-
ited due to its rarity and the heterogeneity of subtypes. METHODS: We attempt to 
collect clinical approved evidences for the efficacy and safety of pralatrexate as 
a salvage treatment for relapsed/refractory PTCL by systematic review. Searches 
based on According to National Comprehensive Cancer Network (NCCN) Guidelines 
and explicit inclusion criteria and exclusion criteria are set for literature search-
ing in PubMed, Cochrane Library and Web of Science. We evaluate primary effi-
cacy outcome (ORR and 95% CI), secondary efficacy outcomes (overall survival and 
progression-free survival duration) and safety outcomes. RESULTS: Twenty-four 
studies were initially identified for abstract screening. After further checking by 
two independent reviewers, 11 records eligible for full-text reviews. A total of 351 
relapsed/refractory PTCL patients were investigated from 11 studies. The median age 
for those treated with pralatrexate were ranged from 45 to 61.5. Before ORRs were 
compared, we adjusted the severity of diseases due to heterogeneous distribution 
of PTCL subtypes. CONCLUSIONS: Our study results indicate that pralatrexate is 
the salvage treatment of choice for the heavily pretreated patients.
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OBJECTIVES: In the era of personalized medicine, oncologists seek to tailor treatments 
for their patients based on indicators of differential response to treatment. The objec-
tive of this study was to estimate the survival benefit associated with androgen depri-
vation therapy (ADT) receipt in elderly Medicare patients newly diagnosed with Stage 
4 metastatic (S4M1) prostate cancer across patient subgroups defined by Gleason 
score and age. METHODS: We analyzed elderly men diagnosed with S4M1 prostate 
cancer between 2004-2009 in the SEER-Medicare datasets and followed through 2010 
or until loss to follow-up. An inverse probability weighted Cox proportional hazards 
model with ADT-by-age and ADT-by-Gleason score interaction terms was used to 
estimate overall survival (OS) and prostate cancer-specific survival (PCSS). RESULTS: 
Among 4,691 patients, 3,426 (73%) men received ADT within the first 6 months of 
diagnosis and 1,265 (27%) men did not receive any form of ADT (median follow-up: 17 
months). There were 3,173 total deaths in the cohort, 1,923 (61%) deaths of which were 
due to prostate cancer. Compared to the non-ADT group, ADT users had a 52%, 39%, 
59%, and 62% relative reduction in the risk of all-cause death in men aged 66-70, 71-75, 
76-80, and 80+, respectively (statistically significant; based on stratified hazard ratios 
from the Cox model). A similar trend was observed for PCSS for the age subgroups. 
Compared to the non-ADT group, ADT users had a 54% and 57% relative reduction in 
the risk of all-cause deaths and prostate cancer-specific deaths in men with Gleason 
8-10, respectively. However, the startified hazard ratios for Gleason < 8 showed no OS 
benefit (Gleason 2-6: [1.4 (0.79-2.44)] and Gleason 7: [0.88 (0.68-1.14)] or PCSS benefit 
(Gleason 2-6: [1.09 (0.53-2.20)]; Gleason 7: [1.05 (0.72-1.51)]. CONCLUSIONS: ADT was 
beneficial in terms of OS and PCSS for all age and Gleason score subgroups except 
men with Gleason score 2-6 and 7.
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OBJECTIVES: Statins may have protective effects against hepatocellular can-
cer, but no studies have focused on their clinical interactions with nucleoside 
analogues(NAs) in patients with chronic hepatitis B virus (HBV) infection. The pur-
pose of this study was to investigate the association between the use of NAs, statins 
and the risk of hepatocellular carcinoma (HCC) in HBV-infected patients. METHODS: 
A population-based matched cohort study of 91,265 HBV-infected patients enrolled 
in the Taiwan National Health Insurance Research Database since October, 2003 and 
December, 2010. 18,253 patients with NAs use were 1:4 matched as 73,012 patients 
without NAs use according to index date, age, sex, diabetes, liver cirrhosis, hyper-
tension, hyperlipidemia, biliary tract stones, chronic renal injury, alcohol related 
diseases, and COPD. Cox proportional hazards regression model for drug expo-
sures was employed to evaluate the association between NAs, statin use and HCC 
risk. RESULTS: 2841 patients were diagnosed with HCC during 262489.6 person-
years; the overall incidence rate was 1082.3 cases per 100,000 person-years or 1% per 
year. The mean follow-up time was 2.9 years. We observed a significantly lower risk 
of HCC among NAs users than among non-users (adjusted HR, 0.42; 95%CI, 0.37-0.48) 
after controlling for potential confounders, which was also found in statin users. 
In addition, we found there was a synergistic effect on NAs and statins uses. The 
adjusted HRs were 0.27 (95%CI, 0.12–0.59), 0.42 (95%CI, 0.37–0.48), and 0.62 (95%CI, 
0.47–0.84) for patients with both NAs, statin user, only NAs user, only statin user 
when comparing with non-users. CONCLUSIONS: NAs are effective in suppressing 
HBV replication and in ameliorating HBV related liver disease. Statins may have 
protective effects against hepatocellular cancer, and our study found there was a 
synergistic effect on HCC risk reduction of NAs and statins use.
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with supplementary information from study protocols, clinical study reports, and 
prescribing information. The trials were evaluated for any potential threats to study 
validity, such as selection bias, performance bias, and assessment bias, as well as the 
likelihood for chance effects instead of true effects. A detailed analysis of attrition 
(discontinuation or loss to follow up), which is a frequent issue in oncology studies, 
was also conducted to assess the presence of attrition bias. RESULTS: The integrated 
analysis and three pivotal trials were found to be of high-quality evidence and at 
low risk of bias and chance effects. Important quality features included a robust 
randomization process, high likelihood of patients remaining balanced and blinded 
throughout the study, as well as a high degree of adherence to assigned treatments. 
These and other factors, such as balance in co-interventions and in rates and reasons 
for discontinuation, make bias from attrition unlikely. CONCLUSIONS: The critical 
appraisal confirmed that the results of the integrated analysis and three pivotal trials 
were robust, with denosumab providing clinically meaningful benefit in patients with 
bone metastases from advanced cancer.
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OBJECTIVES: Clinical studies of metformin in certain cancer types have demonstrated 
decreases in incidence and improvements in therapeutic response. Preclinical evi-
dence supports multiple potential molecular pathways through which metformin 
may impart beneficial effects which impede the development and growth of head 
and neck cancer (HNC). We investigated the impact of metformin exposure following 
a diagnosis of HNC on the risk of all-cause mortality in a population-based cohort 
of Italian patients. METHODS: We used the Italian Emilia-Romagna Regional (RER) 
longitudinal healthcare database to conduct a retrospective cohort study following 
approximately 4 million adults (> = 18) from 2003 to 2011. The RER database captures 
de-identified, fully-linkable demographic, hospital discharge including ICD-9 diag-
nostic and procedure codes, outpatient pharmacy, and specialty data for all residents 
of the region. Resection status and metastases were used to stage the HNC patients 
based on surgical procedures and secondary malignancies. Cox proportional hazard 
methods were used to model the covariate-adjusted time-dependent medication 
exposure survival association to minimize potential immortal-time-bias. RESULTS: 
During the study period, we identified 7,872 patients diagnosed with HNC after which 
708 (8.99%) were exposed at some point to metformin and 3,626 (46.1%) died during 
follow-up (median = 2.98 years). Among them, after adjusting for potential confound-
ers, we found no significant association between exposure to metformin and reduced 
risk of all-cause mortality (HR= 1.03, 95% CI: 0.84 – 1.26). CONCLUSIONS: Our large 
population-based cohort study failed to find an advantage in survival outcomes for 
HNC cancer patients exposed to metformin, despite in-vitro mechanistic viability. 
Further research will be critical in clearly defining the role of metformin in HNC 
cancer survival using similar modeling approaches.
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OBJECTIVES: The aim of the study was to identify and characterize long term survival 
population of advanced non–small-cell lung cancer patients treated with immuno-
therapy. METHODS: Data from 717 patients coming from two expanded used program 
and from two randomized trials evaluating the efficacy of CIMAvaxEGF and Vaxira 
in patients with advanced NSCLC, were used. Mixture models were fitted to Overall 
Survival with one or two population components. All analyzes were made using the 
NLMIXED procedure in SAS. We used the diagnostic tools provided by this procedure 
to check the models’ good of fit properties. The characterization of the two popula-
tions based in prognostic factors was done by classification tree models using RPART 
package in R. RESULTS: Two months of overall survival (OS) benefit were showed for 
CIMAvaxEGF and for Vaxira. The optimal mixture model with the fewest number of 
parameters that adequately describes the time survival data is a mixture model with 
2 component distributions. Components represent short-term and long-term survival 
subpopulations. The proportions of the long term population increase with immu-
notherapy in 22% of patients for Vaxira and 18% for CIMAvaxEGF. The OS benefit was 
different for both subpopulation for both vaccines (vaxira: 2.08 months and 8.7 of OS 
benefit for short- and long- term survival populations respectively; CIMAvaxEGF: 1.96 
months and 14.36 months of OS benefit for short- and long- term survival populations 
respectively). The performance status and the age were essential in the classifica-
tion of the two populations. CONCLUSIONS: The results confirm that there are two 
subgroups among NLCLC patients. The separate analysis of subgroups can give more 
power to the evaluation of clinical trials. The use of mixture models in the analysis 
has implications for the design of new clinical trials. The use of classification trees 
allowed a good characterization of the two populations.
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OBJECTIVES: Pralatrexate, the first drug to gain US FDA approval for treatment 
of relapsed/refractory peripheral T-cell lymphomas (PTCL) in 2009, was aimed to 
